Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a single center, two-period, randomized study to evaluate the Bioequivalence of VHX-896 Tablets Relative to Iloperidone Tablets in Healthy Volunteers
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sequence A: VHX-896 then iloperidone | Experimental |
| |
| Sequence B: Iloperidone then VHX-896 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| VHX-896 and iloperidone | Drug | oral tablet |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Bioequivalence between VHX-896 tablets relative to iloperidone tablets | as measured by plasma concentrations | 96 hours |
| Assessment of Safety and Tolerability of a single dose of VHX-896 | As measured by the incidence of adverse events and clinically significant changes in laboratory values, ECG parameters, and vital signs | 17 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Vanda Investigational Site | Springfield | Missouri | 65802 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C081732 | iloperidone |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Iloperidone and VHX-896 |
| Drug |
oral tablet |
|